Advertisement

PharmacoEconomics & Outcomes News

, Volume 781, Issue 1, pp 30–30 | Cite as

Risk-stratified DMARD tapering feasible in RA, reduces costs

Clinical study
  • 11 Downloads

References

  1. 1.
    Hagen M, et al. Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission. 18th Annual Congress of the European League Against Rheumatism : abstr. OP0249, 14 Jun 2017. Available from: URL: https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=358578.
  2. 2.
    EULAR Press Office. NEW RELAPSE PREDICTION TOOL REDUCES COST OF RHEUMATOID ARTHRITIS TREATMENT. Internet Document : 16 Jun 2017. Available from: URL: https://www.eular.org/congresspressreleases/New_relapse_prediction_tool_reduces_cost_of_rheumatoid_arthritis_treatment__OP0249.pdf.

Copyright information

© Springer International Publishing AG  2017

Personalised recommendations